Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Stone

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Pharmaceutical Statistics|September 23, 2009
The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trialsAndrew Stone
The Australian Journal of Physiotherapy|May 22, 2008
The brachial plexus provocation testAndrew Stone, Michele Sterling
Journal of Biopharmaceutical Statistics|August 21, 2013
Research outcomes and recommendations for the assessment of progression in cancer clinical trialsWill Bushnell, Andrew Stone
Statistical Methods in Medical Research|September 10, 2010
Multiplicity adjustments in trials with two correlated comparisons of interestNikki Fernandes, Andrew Stone
Pharmaceutical Statistics|May 10, 2014
Can a treatment be licenced on the basis of post-treatment predictive biomarkers?Andrew Stone, Nicola Schmitt
Breast Cancer Research : BCR|May 1, 2015
Endocrine therapy: defining the path of least resistanceAndrew Stone, Elizabeth A Musgrove
Pharmaceutical Statistics|May 25, 2013
Strong control over multiple endpoints: are we adding value to the assessment of medicines?Andrew Stone, Christy Chuang-Stein
Journal of Shoulder and Elbow Surgery|July 6, 2023
Sensitivity and specificity of the posterolateral rotatory drawer test in the diagnosis of lateral collateral ligament insufficiency of the elbowAndrew Stone, Shruti Venkatakrishnan, Joideep Phadnis
Contemporary Clinical Trials|July 18, 2006
Improving the design of phase II trials of cytostatic anticancer agentsAndrew Stone, Catherine Wheeler, Alan Barge
Pharmaceutical Statistics|February 14, 2012
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpointsMartin Jenkins, Andrew Stone, Christopher Jennison
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Pharmaceutical Statistics|September 23, 2009
The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trialsAndrew Stone
The Australian Journal of Physiotherapy|May 22, 2008
The brachial plexus provocation testAndrew Stone, Michele Sterling
Journal of Biopharmaceutical Statistics|August 21, 2013
Research outcomes and recommendations for the assessment of progression in cancer clinical trialsWill Bushnell, Andrew Stone
Statistical Methods in Medical Research|September 10, 2010
Multiplicity adjustments in trials with two correlated comparisons of interestNikki Fernandes, Andrew Stone
Pharmaceutical Statistics|May 10, 2014
Can a treatment be licenced on the basis of post-treatment predictive biomarkers?Andrew Stone, Nicola Schmitt
Breast Cancer Research : BCR|May 1, 2015
Endocrine therapy: defining the path of least resistanceAndrew Stone, Elizabeth A Musgrove
Pharmaceutical Statistics|May 25, 2013
Strong control over multiple endpoints: are we adding value to the assessment of medicines?Andrew Stone, Christy Chuang-Stein
Journal of Shoulder and Elbow Surgery|July 6, 2023
Sensitivity and specificity of the posterolateral rotatory drawer test in the diagnosis of lateral collateral ligament insufficiency of the elbowAndrew Stone, Shruti Venkatakrishnan, Joideep Phadnis
Contemporary Clinical Trials|July 18, 2006
Improving the design of phase II trials of cytostatic anticancer agentsAndrew Stone, Catherine Wheeler, Alan Barge
Pharmaceutical Statistics|February 14, 2012
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpointsMartin Jenkins, Andrew Stone, Christopher Jennison
Pageof 6